日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis

Amivantamab (JNJ-61186372) 是一种 Fc 增强型 EGFR/cMet 双特异性抗体,通过单核细胞/巨噬细胞吞噬作用诱导受体下调和抗肿瘤活性

Smruthi Vijayaraghavan, Lorraine Lipfert, Kristen Chevalier, Barbara S Bushey, Benjamin Henley, Ryan Lenhart, Jocelyn Sendecki, Marilda Beqiri, Hillary J Millar, Kathryn Packman, Matthew V Lorenzi, Sylvie Laquerre, Sheri L Moores

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors

针对 EGFR 和 cMet 的新型双特异性抗体对 EGFR 抑制剂耐药性肺癌有效

Sheri L Moores, Mark L Chiu, Barbara S Bushey, Kristen Chevalier, Leopoldo Luistro, Keri Dorn, Randall J Brezski, Peter Haytko, Thomas Kelly, Sheng-Jiun Wu, Pauline L Martin, Joost Neijssen, Paul W H I Parren, Janine Schuurman, Ricardo M Attar, Sylvie Laquerre, Matthew V Lorenzi, G Mark Anderson